# Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™

> **NCT00445185** · PHASE3 · COMPLETED · sponsor: **Henogen** · enrollment: 102 (estimated)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** Henogen HB vaccine
- **BIOLOGICAL:** Fendrix vaccine

## Key facts

- **NCT ID:** NCT00445185
- **Lead sponsor:** Henogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-07
- **Final completion:** 2009-11
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2009-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00445185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00445185, "Study Evaluating Persistence of Anti-HBs Antibodies in Uraemic Patients Receiving Henogen's HBV Vaccine, or Fendrix™". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00445185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*